VYGR · Company research
Voyager Therapeutics, Inc. Common Stock (VYGR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
14records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Voyager Therapeutics (VYGR) Slips 7.35% to $2.27 as Selling Pressure Builds - Social Sentiment - https://www.siam.in/ | Voyager Therapeutics (VYGR) Slips 7.35% to $2.27 as Selling Pressure Builds - Social Sentiment https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 13, 2026 | neutral | 0 | 0.6 |
| Voyager Therapeutics (NasdaqGS:VYGR) Stock Forecast & Analyst Predictions - Simply Wall Street | Voyager Therapeutics (NasdaqGS:VYGR) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 12, 2026 | neutral | 0 | 0.6 |
| Voyager Therapeutics (VYGR) Rises 2.22% as Shares Hold Ground Between $3.29 Support and $3.63 Resistance - IV Spike - www.dars.gov.et | Voyager Therapeutics (VYGR) Rises 2.22% as Shares Hold Ground Between $3.29 Support and $3.63 Resistance - IV Spike www.dars.gov.et | View source ↗ | www.dars.gov.et | Sep 4, 2026 | neutral | 0 | 0.6 |
| Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist - Simply Wall Street | Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist Simply Wall Street | View source ↗ | Simply Wall Street | Aug 8, 2026 | neutral | 0 | 0.6 |
| Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance | Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 6, 2026 | neutral | 0 | 0.6 |
| Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early - Simply Wall Street | Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early Simply Wall Street | View source ↗ | Simply Wall Street | Jul 14, 2026 | neutral | 0 | 0.6 |
| Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money - 24/7 Wall St. | Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Jul 2, 2026 | neutral | 0 | 0.6 |
| Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside - Yahoo Finance | Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside Yahoo Finance | View source ↗ | Yahoo Finance | Jun 30, 2026 | neutral | 0 | 0.6 |
| VYGR Forecast — Price Target — Prediction for 2027 - TradingView | VYGR Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 27, 2026 | neutral | 0 | 0.6 |
| Voyager Receives FDA IND Clearance for VY1706, First Gene - GlobeNewswire | Voyager Receives FDA IND Clearance for VY1706, First Gene GlobeNewswire | View source ↗ | GlobeNewswire | Jun 1, 2026 | neutral | 0 | 0.6 |
| Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026 - Seeking Alpha | Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026 Seeking Alpha | View source ↗ | Seeking Alpha | Apr 13, 2026 | neutral | 0 | 0.6 |
| $VYGR stock is up 19% today. Here's what we see in our data. - Quiver Quantitative | $VYGR stock is up 19% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Mar 10, 2026 | neutral | 0 | 0.6 |
| Voyager Therapeutics, Inc. (VYGR) Stock Price: Oct 8 Close $2.37 - Gotrade | Voyager Therapeutics, Inc. (VYGR) Stock Price: Oct 8 Close $2.37 Gotrade | View source ↗ | Gotrade | Feb 5, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Jan 2, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.